- Home
- KMDA vs TNGX Comparison
KMDA vs TNGX Comparison
Compare KMDA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- TNGX
- Stock Information
- Founded
- KMDA 1990
- TNGX 2014
- Country
- KMDA Israel
- TNGX United States
- Employees
- KMDA N/A
- TNGX N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- KMDA Health Care
- TNGX Health Care
- Exchange
- KMDA Nasdaq
- TNGX Nasdaq
- Market Cap
- KMDA 380.7M
- TNGX 317.4M
- IPO Year
- KMDA N/A
- TNGX N/A
- Fundamental
- Price
- KMDA $6.89
- TNGX $1.40
- Analyst Decision
- KMDA Strong Buy
- TNGX Strong Buy
- Analyst Count
- KMDA 3
- TNGX 7
- Target Price
- KMDA $14.67
- TNGX $12.33
- AVG Volume (30 Days)
- KMDA 53.8K
- TNGX 579.6K
- Earning Date
- KMDA 05-14-2025
- TNGX 05-12-2025
- Dividend Yield
- KMDA 2.89%
- TNGX N/A
- EPS Growth
- KMDA 66.67
- TNGX N/A
- EPS
- KMDA 0.25
- TNGX N/A
- Revenue
- KMDA $160,953,000.00
- TNGX $40,990,000.00
- Revenue This Year
- KMDA $14.01
- TNGX N/A
- Revenue Next Year
- KMDA $9.24
- TNGX N/A
- P/E Ratio
- KMDA $27.37
- TNGX N/A
- Revenue Growth
- KMDA 12.93
- TNGX 10.09
- 52 Week Low
- KMDA $4.74
- TNGX $1.11
- 52 Week High
- KMDA $9.15
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- KMDA 58.32
- TNGX 50.19
- Support Level
- KMDA $6.69
- TNGX $1.07
- Resistance Level
- KMDA $7.10
- TNGX $1.56
- Average True Range (ATR)
- KMDA 0.16
- TNGX 0.16
- MACD
- KMDA 0.05
- TNGX 0.01
- Stochastic Oscillator
- KMDA 72.00
- TNGX 69.81
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.